Jeyaratnam Caniceus/Pixabay.comVerdiva Bio, a London-based biotech, has raised an extraordinary US$410m in its oversubscribed Series A round, making it potentially the largest Series A ever raised by a U.K.-based biotech company, according to CEO Khurem Farooq.
Tag Archive for: obesity
Photys TherapeuticsNovo Nordiks has licenced Photys Therapeutics PHICS platform to target a single cardiometabolic target. Photys got US$186m upfront.
Wilfried Le Goff (INSERM, Sorbonne Université)Researchers at Sorbonne Paris have discovered that a membrane protein in adipocytes of obese mice and humans changes the lipid composition of adipose tissue macrophages rendering them more inflammatory and reducing insulin resistance.
Eli Lilly & CompanyThe British NICE has defined the conditions for the reimbursement of Eli Lilly’s obesity blockbuster tirzepatide. This makes the UK the first country in which patients do not have to pay for the drug out of their own pocket.
Resalis Therapeutics srlAfter securing an equity investment from French pharma giant Sanofi, Italian gene therapy company Resalis Therapeutics srl has begun enrolling participants for a Phase I study of its obesity gene therapy, RES-010, which converts white adipocytes into brown adipocytes.
Novo NordiskNovo Nordisk is putting down up to US$362m to tap into Ascendis’ TransCon technology for treatments in metabolic and cardiovascular diseases. The pharma powerhouse has its sights set on developing a once-monthly GLP-1 receptor agonist.
By Benff - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=128081038In both, liver fibrosis and resolution of MASH, Novo Nordisk’s GLP1 modulator semaglutide has shown convincing results in the Phase III ESSENCE study suggesting a label extension of the obesity blockbuster.
Resalis/VimeoItalian obesity gene therapy developer Resalis Therapeutics srl has gained an equity investment from French pharma major Sanofi SA sufficient to finance its miRNA-22 antisense blocker RES-010 through Phase II proof-of-concept.
Hayo Therapeutics SASwiss HAYA Therapeutics SA has inked a US$1bn biobuck deal with pharma giant Eli Lilly to discover new lncRNA targets in obesity and related metabolic conditions.
Confo Therapeutics NVBelgian GPCR specialist Confo Therapeutics NV has raised €60m in an Series B financing round led by Ackermans & van Haaren to advance clinical development of two clinical programmes and preclinical candidates to treat rare endocrine diseases and obesity.